Revolutionizing early detection of TNBC: The rise of non-invasive biomarkers and next-gen diagnostic strategies
- 31 December 2025
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 218, 105107
Abstract
No abstract availableKeywords
This publication has 248 references indexed in Scilit:
- DNA methylation biomarkers for noninvasive detection of triple‐negative breast cancer using liquid biopsyInternational Journal of Cancer, 2022
- An Injectable Epigenetic Autophagic Modulatory Hydrogel for Boosting Umbilical Cord Blood NK Cell Therapy Prevents Postsurgical Relapse of Triple‐Negative Breast CancerAdvanced Science, 2022
- Artificial intelligence for assisting cancer diagnosis and treatment in the era of precision medicineCancer Communications, 2021
- Statistical and Bioinformatics Analysis of Data from Bulk and Single-Cell RNA Sequencing Experiments2021
- Clinical utility of circulating tumor cells: an updateMolecular Oncology, 2020
- Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast CancerJAMA Oncology, 2020
- CYPOR is a novel and independent prognostic biomarker of recurrence‐free survival in triple‐negative breast cancer patientsInternational Journal of Cancer, 2018
- Shotgun proteomics of archival triple‐negative breast cancer samplesProteomics – Clinical Applications, 2013
- Establishment of tumor‐specific copy number alterations from plasma DNA of patients with cancerInternational Journal of Cancer, 2013
- Down‐regulation of BRCA1 expression by miR‐146a and miR‐146b‐5p in triple negative sporadic breast cancersEMBO Molecular Medicine, 2011